Post Tessa Therapeutics and Parker Institute for Cancer Immunotherapy Enter into Strategic Alliance Agreement
Post Parker Institute for Cancer Immunotherapy Scientists to Present Research at ASCO 2017 on IDO Pathway Inhibitors, Novel CAR-Ts and the Microbiome’s Potential in Immunotherapy
Post Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and the Cancer Research Institute Announce Collaboration to Accelerate Immuno-Oncology Research